{
  "source": "PA-Notification-Ampyra.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1005-14\nProgram Prior Authorization/Notification\nMedication Ampyra® (dalfampridine)\nP&T Approval Date 5/2010, 5/2011, 5/2012, 5/2013, 5/2014, 5/2015, 5/2016, 5/2017,\n5/2018, 5/2019, 5/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nAmpyra® (dalfampridine) is a potassium channel blocker indicated to improve walking in\npatients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Ampyra will be approved based on both of the following criteria:\na. Diagnosis of multiple sclerosis\n-AND-\nb. Physician confirmation that patient has difficulty walking (e.g., Timed 25-foot Walk)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Ampyra will be approved based on the following criteria:\na. Physician confirmation that the patient’s walking improved with Ampyra therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Ampyra [package insert]. Acorda Therapeutics, Inc. Ardsley, NY. June 2022.\nProgram Prior Authorization/Notification – Ampyra (dalfampridine)\nChange Control\n5/2014 Annual review with no change to criteria.\n5/2015 Annual review with no changes to clinical criteria. Deleted educational\nstatement and updated references.\n5/2016 Annual review. Updated criteria to r",
    "4 Annual review with no change to criteria.\n5/2015 Annual review with no changes to clinical criteria. Deleted educational\nstatement and updated references.\n5/2016 Annual review. Updated criteria to require only a diagnosis. Updated\nreferences.\n5/2017 Annual review with no changes to criteria.\n5/2018 Annual review with no changes to clinical criteria. Updated references.\n12/2018 Administrative change to add statement regarding use of automated\nprocesses.\n5/2019 Annual review with no changes to clinical criteria.\n5/2020 Annual review with no changes to clinical criteria. Updated reference.\n5/2021 Annual review with no changes to clinical criteria.\n5/2022 Annual review with no change to clinical criteria. Updated reference.\n5/2023 Annual review with no change to clinical criteria. Added state mandate\nfootnote. Updated reference.\n5/2024 Annual review. Initial Authorization increased to 12 months.\n5/2025 Annual review with no change to clinical criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}